Hepatocellular Carcinoma
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
SBRT with sorafenib is shown to be associated with a clinically important but not statistically significant improved OS rate.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Advertisement
Expert Interviews on GI Oncology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.